Riskpilot← Back to searchSign inGet full accessLexor Sweden AB
ABActiveOrg 5567766364Ringestensvägen 4General medical practice activities · NACE 8621Est. 20091 employees
Revenue 2025
SEK 2,5M
+17% vs 2024
EBITDA margin
4.0%
-46% vs 2024
Equity ratio
36.3%
Financial strength
Net profit 2025
SEK 74K
-46% vs 2024
| Revenue | SEK 2,5M | +17% |
| EBITDA | SEK 99K | -46% |
| Net profit | SEK 74K | -46% |
| Total assets | SEK 807K | +30% |
| Equity | SEK 293K | -14% |
| Employees | 1 | — |
Legal name
Lexor Sweden AB
Org number
5567766364
Legal form
Aktiebolag
NACE code
8621 · General medical practice activities
Founded
22 januari 2009
Share capital
SEK 100 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Aktiebolaget ska bedriva läkarverksamhet, utbildning, utveckling och rådgivningsverksamhet inom nämnda område, forskningsverksamhet, handel med nämnda områdens produkter och maskiner samt därmed förenlig verksamhet.
Address
Ringestensvägen 4
Email
tommy.berglund@lexor.one
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 2 213 | 1 969 | 2 004 | 2 103 | 2 456 |
| Staff expenses | — | — | −1 396 | −1 394 | −1 561 |
| EBITDA | 221 | −3 | 221 | 181 | 99 |
| Depreciation & amort. | −0 | −20 | −140 | — | — |
| EBIT | 221 | −23 | 81 | 181 | 99 |
| Net financials | −309 | −314 | −157 | −4 | 3 |
| Profit before tax | 60 | −187 | −76 | 178 | 102 |
| Tax | −47 | −0 | −12 | −42 | −28 |
| Net profit | 13 | −187 | −88 | 136 | 74 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 1 164 | 1 164 | 862 | 618 | 807 |
| Equity | 628 | 291 | 203 | 339 | 293 |
| Long-term debt | 93 | 354 | 286 | 0 | — |
| Short-term debt | 443 | 520 | 373 | 279 | 514 |
| Total debt | 536 | 874 | 659 | 279 | 514 |
EBITDA margin
4.0%
This company
15.8%
Market median
-75% vs market
20212025
Equity ratio
36.3%
This company
38.2%
Market median
+5% vs market
20212025
Return on equity
25.2%
This company
18.4%
Market median
+37% vs market
20212025
Net profit margin
3.0%
This company
8.1%
Market median
-63% vs market
20212025
Asset turnover
3.04×
This company
1.12×
Market median
+171% vs market
20212025
Debt / equity
1.76×
This company
0.62×
Market median
-184% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Former (1) | ||
PP | Audit | 2022 – 2023 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2022 | |
| Deputy Board Member | 2022 | |
| Former (1) | ||
| Deputy Board Member | 2022 – 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Lexor Sweden AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Peter-Olof Pettersson | Audit | 0 companies |
| Kent Tommy Berglund | Board of Directors | 0 companies |
| Sheida Daroudi | Deputy Board Member | 0 companies |
| Kent Johan Berglund | Deputy Board Member | 0 companies |